Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Cure Today1d
Linvoseltamab BLA Resubmission Accepted by FDA for Review
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...
pulmonologyadvisor2d
COVID Antiviral, mAb Treatments Reduce Mortality and Hospitalization Rates
Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.
BioSpace2d
Vir Leans Into Immunology Roots After Flamed-Out COVID Fame
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
News Medical3d
Inhaled antibody therapy shows promise for COVID-19 treatment
The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.